Investors/Media

February 17, 2021
SAN FRANCISCO --(BUSINESS WIRE)--Feb. 17, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in
January 6, 2021
-CAHmelia Adult Classic CAH Program Underway in U.S. and Europe - -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Syndrome Program Anticipated in Second Half of 2021- -New Patent Issuance Extends Tildacerfont Patent
Displaying 11 - 14 of 14